Zobrazeno 1 - 10
of 374
pro vyhledávání: '"BEZ235"'
Autor:
Yen-Hsiang Huang, Ling-Yen Chiu, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Chang-Han Chen, Gwo-Tarng Sheu, Tsung-Ying Yang
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 1, p 616 (2024)
Lung cancer is considered the number one cause of cancer-related deaths worldwide. Although current treatments initially reduce the lung cancer burden, relapse occurs in most cases; the major causes of mortality are drug resistance and cancer stemnes
Externí odkaz:
https://doaj.org/article/96f26bb647c9460686d3a1abd69287df
Publikováno v:
Iranian Journal of Immunology, Vol 19, Iss 1, Pp 58-70 (2022)
Background: Several PI3K/Akt/mTOR pathway inhibitors and TLR agonists induce tumor cell death. However, the mechanisms of these therapeutic approaches in acute myeloid leukemia (AML) cells are still unknown. Objectives: To investigate the effects of
Externí odkaz:
https://doaj.org/article/7da66f9f1b084d19b5c094bba5ba51c2
Autor:
Hu Y, Zhang K, Zhu X, Zheng X, Wang C, Niu X, Jiang T, Ji X, Zhao W, Pang L, Qi Y, Li F, Li L, Xu Z, Gu W, Zou H
Publikováno v:
International Journal of Nanomedicine, Vol Volume 16, Pp 2173-2186 (2021)
Yali Hu,1,2,* Kunpeng Zhang,1,* Xingyao Zhu,1,* Xiuyan Zheng,1 Chao Wang,1 Xiao Niu,1 Teng Jiang,1 Xinhua Ji,1 Weilin Zhao,1 Lijuan Pang,1 Yan Qi,1 Feng Li,1,3 Li Li,4 Zhiping Xu,4 Wenyi Gu,4 Hong Zou1 1Department of Pathology, The First Affiliated H
Externí odkaz:
https://doaj.org/article/f243e3f03cd7469f9deb1c4c0d27bb34
Autor:
Fabian Lang, Lydia Wunderle, Susanne Badura, Eberhard Schleyer, Monika Brüggemann, Hubert Serve, Susanne Schnittger, Nicola Gökbuget, Heike Pfeifer, Sebastian Wagner, Kevin Ashelford, Gesine Bug, Oliver G. Ottmann
Publikováno v:
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-14 (2020)
Abstract Background Combined inhibition of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) complexes may be an efficient treatment for acute leukemia. The primary objective of this phase I single center open label st
Externí odkaz:
https://doaj.org/article/feda2fbc95de41e789dcb412107b0d8e
Autor:
Xiaolong Tang, Amin Li, Chunmei Xie, Yinci Zhang, Xueke Liu, Yinghai Xie, Binquan Wu, Shuping Zhou, Xudong Huang, Yongfang Ma, Weiya Cao, Ruyue Xu, Jing Shen, Zhen Huo, Shuyu Cai, Yong Liang, Dong Ma
Publikováno v:
Nanoscale Research Letters, Vol 15, Iss 1, Pp 1-16 (2020)
Abstract Polymer materials encapsulating drugs have broad prospects for drug delivery. We evaluated the effectiveness of polyethylene glycol-poly (lactic-co-glycolic acid) (PLGA-PEG) encapsulation and release characteristics of PI3K/mTOR inhibitor NV
Externí odkaz:
https://doaj.org/article/cceb3d7ebd9347cb83e159c2cd20043e
Publikováno v:
Current Research in Pharmacology and Drug Discovery, Vol 3, Iss , Pp 100117- (2022)
The mammalian target of rapamycin (mTOR) plays an important role in the aggressiveness and therapeutic resistance of many cancers. Targeting mTOR continues to be under clinical investigation for cancer therapy. Despite the notable clinical success of
Externí odkaz:
https://doaj.org/article/a0759ec0680e4a8b80c895a92cffa305
Autor:
Marika Colombo, Federico Passarelli, Paola A. Corsetto, Angela M. Rizzo, Mirko Marabese, Giulia De Simone, Roberta Pastorelli, Massimo Broggini, Laura Brunelli, Elisa Caiola
Publikováno v:
Cells, Vol 11, Iss 23, p 3719 (2022)
Hyperactivation of the phosphatidylinositol-3-kinase (PI3K) pathway is one of the most common events in human cancers. Several efforts have been made toward the identification of selective PI3K pathway inhibitors. However, the success of these molecu
Externí odkaz:
https://doaj.org/article/20cbd17b052c4874ac7b37c2b3b6df0f
Autor:
Matt Kaeberlein
Publikováno v:
Translational Medicine of Aging, Vol 4, Iss , Pp 32-34 (2020)
The biopharmaceutical company resTORbio, Inc. Recently announced termination of a phase 3 clinical trial evaluating the ability of the drug RTB101 to improve immune function in the elderly. The company reported that the first stage of the PROTECTOR1
Externí odkaz:
https://doaj.org/article/77adc81e4a9b48d38a947207228ec188
Publikováno v:
Cancer Management and Research, Vol Volume 11, Pp 7933-7951 (2019)
Pengliang Xin,1 Wenqian Xu,1 Xiongpeng Zhu,1 Chuntuan Li,1 Yan Zheng,1 Tingjin Zheng,2 Wenzhao Cheng,3 Qunyi Peng11Department of Haematology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, People’s Republic of China; 2Ce
Externí odkaz:
https://doaj.org/article/caf5699834014e4da872756cf81c34c4
Autor:
Yi-Ying Wu, Hung-Chang Wu, Jia-En Wu, Kuo-Yen Huang, Shuenn-Chen Yang, Si-Xuan Chen, Chao-Jung Tsao, Keng-Fu Hsu, Yuh-Ling Chen, Tse-Ming Hong
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-16 (2019)
Abstract Background Lung cancer is the most common cause of cancer-related mortality worldwide despite diagnostic improvements and the development of targeted therapies, notably including epidermal growth factor receptor (EGFR) tyrosine kinase inhibi
Externí odkaz:
https://doaj.org/article/2e6aa94a9f954f8aa464390326c8d1d3